FcRH4 Inhibitors
FcRH4 inhibitors are chemical compounds that specifically target Fc receptor-like protein 4 (FcRH4), a member of the Fc receptor-like family of proteins. FcRH4, also known as FCRL4, is primarily expressed on a subset of B cells, particularly tissue-resident memory B cells, and plays a significant role in modulating immune responses. These inhibitors function by disrupting the interaction between FcRH4 and its ligands or associated molecules, thereby altering the signal transduction pathways mediated by this receptor. FcRH4 is involved in inhibitory signaling that affects B cell activation, proliferation, and differentiation, meaning inhibitors of this receptor are designed to interfere with these processes at the molecular level. Structurally, these inhibitors are often small molecules or biologically derived peptides that can bind with high specificity and affinity to the FcRH4 receptor.
In terms of chemical structure, FcRH4 inhibitors are designed to engage key binding sites on the extracellular domain of the FcRH4 receptor. Some inhibitors may function by mimicking endogenous ligands or by allosterically modulating the receptor, preventing its activation. The binding of these compounds to FcRH4 triggers a conformational change in the receptor, which interferes with downstream signaling pathways that typically lead to altered immune cell functions. Due to the structural complexity of the FcRH4 receptor, the design of these inhibitors often involves detailed computational modeling and structure-activity relationship (SAR) studies to ensure that the compounds achieve a high level of precision and selectivity. Furthermore, the development of FcRH4 inhibitors requires rigorous optimization to improve their binding efficiency, stability, and overall interaction with the target receptor.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $94.00 $213.00 | 33 | |
Methotrexate may downregulate FcRH4 expression by impeding dihydrofolate reductase, leading to a depletion of thymidylate and purine nucleotides, which are crucial for DNA synthesis and the proliferation of B cells, consequently reducing the expression of FcRH4. | ||||||
hydroxychloroquine | 118-42-3 | sc-507426 | 5 g | $57.00 | 1 | |
Hydroxychloroquine could decrease FcRH4 expression by accumulating in lysosomes, leading to pH elevation and interference with lysosomal enzymes and autophagy, processes that could be linked to the expression levels of FcRH4 in B cells. | ||||||
Chlorambucil | 305-03-3 | sc-204682 sc-204682A | 250 mg 1 g | $52.00 $122.00 | 3 | |
Chlorambucil might lead to a reduction in FcRH4 expression through its alkylating action that causes DNA damage, leading to cell cycle arrest and apoptosis in B cells, thereby decreasing the overall expression of FcRH4 in the surviving B cell population. | ||||||
Cyclophosphamide | 50-18-0 | sc-361165 sc-361165A sc-361165B sc-361165C | 50 mg 100 mg 500 mg 1 g | $90.00 $146.00 $469.00 $791.00 | 18 | |
Cyclophosphamide could inhibit FcRH4 expression by cross-linking DNA strands, introducing cytotoxic lesions that result in apoptotic cell death of B cells. This reduction in B cell numbers could correspond to lower FcRH4 expression levels. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib may contribute to the decrease in FcRH4 expression by preventing the proteasomal degradation of IκB, leading to the inhibition of NF-κB, a transcription factor that controls the expression of multiple genes including those involved in immune responses like FcRH4. | ||||||
Lenalidomide | 191732-72-6 | sc-218656 sc-218656A sc-218656B | 10 mg 100 mg 1 g | $50.00 $374.00 $2071.00 | 18 | |
Lenalidomide could reduce the transcription of FcRH4 by enhancing the degradation of specific transcription factors responsible for its expression, as well as by altering the cytokine environment that is critical for B cell activity and FcRH4 expression. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $111.00 $357.00 | 8 | |
Thalidomide has the potential to suppress FcRH4 expression by inhibiting angiogenesis and altering the microenvironment of B cells, which could lead to a reduction in the cellular signals necessary for the maintenance of FcRH4 expression. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin may suppress FcRH4 expression through the inhibition of the mTOR pathway, which is responsible for cell growth and proliferation. This inhibition could lead to a reduced expression of genes involved in B cell activation, including FcRH4. | ||||||
Azathioprine | 446-86-6 | sc-210853D sc-210853 sc-210853A sc-210853B sc-210853C | 500 mg 1 g 2 g 5 g 10 g | $203.00 $176.00 $349.00 $505.00 $704.00 | 1 | |
Azathioprine could decrease FcRH4 expression by interfering with nucleic acid metabolism, leading to the suppression of lymphocyte proliferation, thereby potentially decreasing the number of B cells expressing FcRH4. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
JQ1 might inhibit FcRH4 expression by binding to bromodomains and displacing transcription factors from chromatin, leading to transcriptional repression of target genes, which could include those governing the expression of FcRH4 in B cells. | ||||||